+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 39 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating a new treatment for adults with borderline personality disorder BPD who experience suicidal thoughts. This study aims to assess how many participants complete the treatment, how they feel about it, whether it causes changes in brain activity, if it improves BPD symptoms, and whether any benefits last over time. The research is sponsored by Mclean Hospital and involves a pilot trial of combined therapy. Participants will take a single dose of the medication D-cycloserine the night before the treatment day. On the treatment day, they will receive up to 20 short sessions of transcranial magnetic stimulation TMS, each lasting about 3 minutes and separated by 30-minute breaks, lasting up to 12 hours total. This is an open-label study without a comparison group. Throughout the study, participants will visit the clinic for interviews and testing. They will complete weekly questionnaires for 4 weeks before treatment and for 6 weeks after the treatment day. Researchers will measure acceptability of the intervention, brain activity changes using motor-evoked potentials, and BPD symptom scales at multiple time points to track outcomes and safety over about 11 weeks.

Age: 18Years +All GendersPhase 1Phase 2
1 location
E

Actively Recruiting

Researchers are investigating treatments for treatment-resistant major depressive disorder MDD, a common and disabling condition worldwide. This trial evaluates whether a single day of Rapid Robotically-controlled Transcranial Magnetic Stimulation RRTMS combined with the investigational drug NRX-101 a combination of D-cycloserine and lurasidone can improve clinical response and remission compared to sham TMS or placebo. The study seeks to develop a rapid and durable treatment alternative for patients who do not respond well to existing therapies, especially those with demanding jobs such as military personnel and first responders. Participants will receive one of three treatments on the day of intervention RRTMS with NRX-101, RRTMS with placebo, or sham TMS with NRX-101. The RRTMS procedure is performed with a neuronavigated robotic system delivering theta burst pulses. NRX-101 consists of oral doses of D-cycloserine and lurasidone. Sham TMS uses a device configured not to deliver effective brain stimulation. This randomized, double-blind trial will enroll 240 adults and compare outcomes at six weeks post-treatment. Throughout the study, participants will be assessed for depression severity and suicidality using standardized scales such as the Montgomery-sberg Depression Rating Scale MADRS and the Columbia Suicide Severity Rating Scale CGI-SS. Additional measures include response and remission rates and depression symptom questionnaires. The trial includes monitoring for adherence, adverse events, and safety. Participation lasts at least six weeks, with evaluations to determine the treatments impact on depression and suicidality.

Age: 18Years - 80YearsAll GendersPhase 2Phase 3
3 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of brenipatide combined with standard treatment compared to placebo with standard treatment in adults with schizophrenia. This phase 2 study aims to understand how brenipatide affects body weight and other clinical measures in this population. The trial is sponsored by Eli Lilly and Company and includes adults aged 18 to 55 years diagnosed with schizophrenia. Participants will be randomly assigned to receive either brenipatide or placebo, both administered by subcutaneous injection alongside their usual schizophrenia care. The study is double-blind, meaning neither participants nor researchers will know who receives the active drug or placebo. The trial consists of three periods a screening period of about one month, a treatment period lasting up to 12 months, and a follow-up period of approximately two months. During the study, participants will attend regular visits for assessments including body weight changes, cognitive testing, symptom severity scales, and functional capacity evaluations. Researchers will also monitor safety through laboratory tests and measure drug levels and immune responses. The total participation time may be up to 15 months, including screening, treatment, and follow-up to evaluate outcomes and safety comprehensively.

Age: 18Years - 55YearsAll GendersPhase 2
101 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of KarXT in adults aged 55 to 90 years with mild to severe Alzheimers Disease that includes moderate to severe psychosis symptoms. This Phase 3 study focuses on treating psychosis related to Alzheimers Disease using a randomized, double-blind, placebo-controlled design. Participants receive either KarXT or a placebo at specified doses on scheduled days. The study lasts up to 14 weeks, during which the impact of KarXT on hallucinations, delusions, and other neuropsychiatric symptoms is assessed. The research also monitors various safety measures and cognitive function throughout this period. During the study, participants undergo evaluations including neuropsychiatric inventories, clinical global impression scales, cognitive tests like the Mini-Mental State Examination and Alzheimers Disease Assessment Scale, as well as safety monitoring through laboratory tests, vital signs, ECGs, and assessments for adverse events. The primary outcome is the change in hallucinations and delusions score up to week 14, with ongoing safety and efficacy assessments throughout the treatment period.

Age: 55Years - 90YearsAll GendersPhase 3
296 locations
S

Actively Recruiting

Researchers are evaluating a custom-formulated, hemp-derived high-CBD product in adults with bipolar disorder who experience anxiety. This pilot open-label clinical trial aims to explore the potential anti-anxiety and antidepressant effects of cannabidiol CBD over four weeks. Despite interest in cannabinoid products, this is the first clinical trial focusing on hemp-derived CBD in this population. Participants will self-administer the high-CBD solution under the tongue twice daily for four weeks. The study involves an initial phone pre-screening, followed by an in-person screening visit with interviews, questionnaires, urine and blood tests, and genetic sampling. Weekly visits, either in person or remote, will monitor mood and quality of life, ending with a final visit to complete more assessments and cognitive testing. Throughout the study, participants will complete various clinical and quality of life questionnaires, cognitive assessments, and genetic testing. Researchers will measure changes in anxiety using the Beck Anxiety Inventory as the primary outcome, with depression changes as a secondary measure. Safety and adherence will be monitored during weekly visits, and the total participation lasts approximately four weeks after screening and baseline assessments.

Age: 18Years - 65YearsAll GendersPhase 2
1 location
E

Actively Recruiting

Researchers are studying the potential effects of a high-cannabidiol CBD sublingual product on gynecologic pain in individuals with endometriosis, adenomyosis, or chronic pelvic inflammatory disease PID. This clinical trial is double-blind, placebo-controlled, and focuses on understanding specific targets and mechanisms of a hemp-derived, full-spectrum, high-CBD product for managing these conditions. Participants will be randomly assigned to receive one of two doses of the high-CBD product or a placebo. The study involves self-administration of the assigned product three times daily for one week. A subset of participants may undergo additional pharmacokineticpharmacodynamic studies involving extended blood sampling and questionnaires to better understand the bodys response to the CBD product. During the study, participants will attend three visits including screening, baseline, and final visits. These visits include clinical interviews, medical screenings, urine and blood sample collections, questionnaires, and sensory testing. Researchers will measure levels of CBD and its metabolites, inflammatory markers, and circulating anandamide at the start and end of the study. Participants will track their product use and may receive additional compensation if participating in extended procedures. The study aims to assess treatment effects over the 7-day period.

Age: 21Years +FEMALEPhase 1Phase 2
1 location
S

Actively Recruiting

Healthy Volunteer

Researchers are studying the role of the NociceptinOrphanin FQ receptor system in the brains of adults aged 18 to 45 with current or past major depressive disorder MDD. The study aims to understand how this receptor system affects decision-making and brain activity related to approach and avoidance behaviors. It also explores stress-related inflammation and neural markers that may predict future depressive symptoms. Participants will undergo functional magnetic resonance imaging fMRI while performing decision-making tasks, as well as resting positron emission tomography PET scans using a special tracer targeting the NociceptinOrphanin FQ receptor. The study includes people with current MDD, those with a history of MDD, and control subjects without neurological or psychiatric illness. An aversive device delivers mild electrical stimulation to the ankle, and blood will be drawn during PET scans to measure relevant biological markers. During the study, participants will complete clinical interviews, behavioral tasks, and multiple questionnaires assessing mood, stress, and quality of life. Biological samples such as saliva and blood will be collected, and imaging data will be analyzed. Follow-up clinical interviews and assessments will occur at 6 and 12 months after PET scans to monitor changes. The study involves detailed tracking of brain function, behavior, and biological signals over time to better understand depression.

Age: 18Years - 45YearsAll Genders
1 location
E

Actively Recruiting

Researchers are evaluating treatment options for adults aged 18 to 35 experiencing their first episode of psychosis who also have specific genetic markers that may influence their response to antipsychotic medications. The study aims to compare the effects of early treatment with clozapine against standard treatments with risperidone or aripiprazole in patients identified as biomarker positive for better response and lower risk of certain side effects. Participants will be screened using brain imaging rs-fMRI and genetic blood tests to identify three biomarkers related to treatment response, risk of weight gain, and risk of agranulocytosis. Those who meet all biomarker criteria will be randomly assigned to receive clozapine, risperidone, or aripiprazole, each given in titrated doses according to the study protocol. The treatments will be administered under careful monitoring during the study period. Throughout the study, participants will undergo assessments including symptom rating scales like the Brief Psychiatric Rating Scale BPRS, weight monitoring, blood tests for agranulocytosis and neutropenia, and brain scans as needed. These measurements will be taken over 12 weeks to evaluate changes in symptoms and side effects. The study involves regular visits and monitoring to ensure safety and adherence, with the total participation lasting up to 12 weeks after enrollment.

Age: 18Years - 35YearsAll GendersPhase 4
5 locations
S

Actively Recruiting

Researchers are studying the early stages of psychotic disorders such as Schizophrenia, Schizoaffective Disorder, and Bipolar I Disorder to better understand their progression and how biological markers and different patient types may predict treatment response. This observational study involves a large sample across multiple sites, aiming to identify clinical and biological predictors of outcomes to improve personalized care for individuals with early psychosis. Participants receive coordinated specialty care and undergo a series of assessments including brain scans MRI, eye-tracking, EEG, DNA collection, and neuropsychological testing at baseline and follow-up visits at 1, 6, and 12 months. These procedures help gather data on brain function, genetics, and cognitive abilities. The study categorizes participants into biotypes based on biomarker profiles to explore their relation to treatment outcomes. Participants are involved for about one year, attending four visits where clinical interviews, cognitive tests, and biomarker assessments are conducted. Screening takes about three hours and includes drug and pregnancy testing, psychiatric and medical history reviews. Researchers track outcomes such as treatment response, symptomatic and functional remission, and relapse over the study period to gain insight into early psychosis and guide future care strategies.

Age: 18Years - 40YearsAll Genders
6 locations
E

Actively Recruiting

Researchers are studying cognition in psychotic disorders such as schizophrenia, bipolar disorder, and schizoaffective disorder. The main goal is to understand if magnetic stimulation can alter processing speed, which is how quickly participants solve challenging cognitive tasks. This trial evaluates if non-invasive brain stimulation can temporarily change brain activity and improve cognitive function in these disorders. Participants will undergo different types of repetitive transcranial magnetic stimulation rTMS including intermittent theta burst stimulation iTBS, continuous theta burst stimulation cTBS, and sham rTMS, which does not significantly change brain activity. Each participant will complete MRI scans and cognitive tests before and after each rTMS session to measure changes in brain circuits and cognitive performance. The study uses a randomized crossover design, so participants receive all three types of stimulation across separate visits. During the trial, participants will perform cognitive tests such as the BACS Symbol Coding and Digit Sequence tests, and undergo functional MRI scans before and after each rTMS session. These assessments take place at specific timepoints around each stimulation visit to capture immediate effects. The researchers will monitor changes in cognitive speed and brain activity, with all procedures conducted under medical supervision. The study spans multiple visits with detailed cognitive and imaging evaluations to assess the impact of brain stimulation on cognition.

Age: 18Years - 55YearsAll GendersPhase Not Applicable
2 locations

1-10 of 39

1